Loading...
•
Jun 30, 2021
ClearPoint Neuro Q2 2021 Earnings Report
Reported record case volume supported clinically during the quarter.
Key Takeaways
ClearPoint Neuro reported a successful second quarter of 2021, highlighted by record case volume, demonstrating a return to pre-pandemic levels ahead of schedule. The company is also working with more than 30 partners in the drug delivery space and expects to add additional partners in the second half of 2021.
Record case volume was achieved, indicating a return to pre-pandemic levels earlier than anticipated.
Clinical and pre-clinical activities by biologics and drug delivery partners have resumed, potentially accelerating therapy regulatory pathways.
The company is collaborating with over 30 partners in the drug delivery sector and anticipates further partnerships in the latter half of 2021.
Development and production teams are on schedule for all programs announced in February, maintaining planned timelines and key milestones.
Revenue by Segment
Forward Guidance
ClearPoint Neuro estimates cases supported by their clinical team will be in the range of 900 - 1000, and revenues will be in the range of $16.0 - $17.5 million for 2021.
Challenges Ahead
- Potential impact from the new Delta wave of COVID-19 cases is being monitored.
- Pressure on elective procedures at several customer sites due to hospital ICU beds filling up.
- COVID-19 pandemic and the measures adopted to contain its spread may impact the company's results.
- Future revenue from sales of the Company’s ClearPoint Neuro Navigation System products is uncertain.
- The Company’s ability to market, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro Navigation System products is not guaranteed.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...